Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2001

View Archived Issues

Company Profile: Zycos

Zometa shows efficacy in treatment of SREs in several tumor types

Structure elucidation reported for highly potent, naturally produced glucose-6-phosphatase inhibitor

Dipeptide Y1 antagonist reduces food intake and body weight gain in rats

Novartis launches Gleevec in U.S. for treatment of CML

Naturally occurring octadecapeptide possesses immunomodulatory properties

Protonix I.V. now available in the U.S. for GERD

ASCO 2001: evidence of antitumor activity, good tolerance reported for Triapine

Repeated doses of chimeric MAb safe and effective in early trial in RCC

AGI Dermatics and Elan form alliance for Dimericine

Company Profile: Checkpoint Genetics

BioTransplant completes acquisition of Eligix

Interim phase II results confirm excellent safety and activity of Allovectin-7 in melanoma

Medarex and NovImmune to codevelop antibody therapeutics

Response and survival data for RSR-13 in NSCLC discussed at ASCO

Telik awarded SBIR grant for cancer drug discovery

Adenosine Therapeutics obtains license from Penn State with diabetes application

Thalomid/Camptosar combination study for metastatic colorectal cancer begins

Mixed 5-HT/dopamine receptor ligands identified by Boehringer Ingelheim

New compounds designed by AstraZeneca useful in cases of excess apoptosis

Angiogenesis inhibitors from Bayer act on KDR kinase

P&G discovers new hydroxamic acid-based MMP inhibitors

Preparation and therapeutic uses of new alpha1A-adrenoceptor antagonists disclosed by Synaptic

Selective PDE5 inhibitors reported by Icos along with potential therapeutic uses

Company Profile: GeneTrol Biotherapeutics

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026